Navigation Links
Crdentia Appoints Debbie Griffith to Director of Business Development, Reporting Directly to CEO
Date:1/10/2008

DALLAS, Jan. 10 /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC Bulletin Board: CRDT), a leading healthcare staffing company, today announced the appointment of Ms. Debbie Griffith, formerly Director of Operations in Houston, Texas, to Director of Business Development. In this newly created position, Ms. Griffith will report directly to CEO, John Kaiser and will be responsible for ensuring that Crdentia branch offices adequately expand their services to keep pace with healthcare staffing industry trends that show rapidly increasing demand for allied health and locum tenens staffing.

"Debbie will play a critical role in assisting smaller Crdentia markets to become a single source, not only for quality nurses, but for healthcare staff of all professions and specialties. Her extensive experience staffing a large range of healthcare professionals and proven ability to successfully diversify revenue sources will be a great asset to our branches," said John Kaiser, CEO.

Ms. Griffith joined Crdentia in July, 2007 and brought with her 16 years of experience gained from management and executive level positions at three large healthcare staffing companies in Houston, Texas, where she was instrumental in negotiating new client contracts, generating revenue streams, increasing recruitment, promoting performance improvements and diversifying business services.

About Crdentia Corp.

Crdentia Corp., one of the nation's leading providers of healthcare staffing solutions, is focused on recruiting talented national and international healthcare professionals to meet the ever-increasing employment needs of over 2,300 clients. Crdentia is one of the few companies that can provide quality temporary staff for all healthcare industry positions including local nurses, travel nurses, allied health, locum tenens and home care professionals. For more information, visit http://www.crdentia.com.

Forward Looking Statements

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, a limited operating history with no earnings; reliance on the Company's management team; the ability to successfully implement the Company's business plan; the ability to continue as a going concern; the ability to fund the Company's business and acquisition strategy; the growth of the temporary healthcare professional staffing business; difficulty in managing operations of acquired businesses; uncertainty in government regulation of the healthcare industry; and limited trading in the public market for the Company's common stock. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Crdentia Corp.

John Kaiser, CEO

Phone: 972.850.0780

Fax: 972.392.2722

jkaiser@crdentia.com

Jim TerBeest, CFO

Phone: 972.850.0780

Fax: 972.392.2722

jterbeest@crdentia.com


'/>"/>
SOURCE Crdentia Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
2. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
3. Crdentias National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentias Travel Nurse Division
4. Crdentia Acquires ATS Health Services
5. Crdentia Announces Completion of $5M Financing
6. Crdentia Announces Appointment of Tim Jones to Senior Management Team
7. Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources
8. WorldHeart Appoints David Pellone Chief Financial Officer
9. Novo Nordisk Appoints New Leader of North American Business
10. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
11. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... 2014. The company had 800 customers and 2,250 RCEs at the time of ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/25/2017)... Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total ... sliders to easily refine their color range. With color spectrum tools users can visually ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The global ... CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. ... from 2016 to 2027. The market is estimated at $816m in ... ... to discover how you can exploit the future business opportunities emerging ...
Breaking Medicine Technology: